MA41174A - Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta - Google Patents

Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Info

Publication number
MA41174A
MA41174A MA041174A MA41174A MA41174A MA 41174 A MA41174 A MA 41174A MA 041174 A MA041174 A MA 041174A MA 41174 A MA41174 A MA 41174A MA 41174 A MA41174 A MA 41174A
Authority
MA
Morocco
Prior art keywords
pi3kbeta
inhibitors
derivatives used
imidazopyridazine derivatives
imidazopyridazine
Prior art date
Application number
MA041174A
Other languages
English (en)
Other versions
MA41174B1 (fr
Inventor
Patrick René Angibaud
Didier Jean-Claude Berthelot
Sophie Coupa
Christophe Gabriel Marcel Demestre
Lieven Meerpoel
Guillaume Jean Maurice Mercey
Laurence Anne Mevellec
Christophe Meyer
Elisabeth Thérèse Jeanne Pasquier
Isabelle Noëlle Constance Pilatte
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA41174A publication Critical patent/MA41174A/fr
Publication of MA41174B1 publication Critical patent/MA41174B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA41174A 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta MA41174B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
EP15810784.7A EP3233862B1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
PCT/EP2015/080604 WO2016097347A1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pι3κβ

Publications (2)

Publication Number Publication Date
MA41174A true MA41174A (fr) 2017-10-25
MA41174B1 MA41174B1 (fr) 2019-09-30

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41174A MA41174B1 (fr) 2014-12-19 2015-12-18 Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta

Country Status (25)

Country Link
US (1) US10087187B2 (fr)
EP (1) EP3233862B1 (fr)
JP (1) JP6568588B2 (fr)
KR (1) KR20170095239A (fr)
CN (1) CN107108634B (fr)
AU (1) AU2015366190B2 (fr)
BR (1) BR112017012930A2 (fr)
CA (1) CA2967551A1 (fr)
CY (1) CY1122381T1 (fr)
DK (1) DK3233862T3 (fr)
EA (1) EA029789B1 (fr)
ES (1) ES2761051T3 (fr)
HR (1) HRP20191550T1 (fr)
HU (1) HUE045220T2 (fr)
IL (1) IL252866B (fr)
LT (1) LT3233862T (fr)
MA (1) MA41174B1 (fr)
MD (1) MD3233862T2 (fr)
ME (1) ME03517B (fr)
MX (1) MX2017008074A (fr)
PL (1) PL3233862T3 (fr)
PT (1) PT3233862T (fr)
RS (1) RS59301B1 (fr)
SI (1) SI3233862T1 (fr)
WO (1) WO2016097347A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102630111B1 (ko) 2015-10-09 2024-01-25 얀센 파마슈티카 엔브이 PI3Kβ 저해제로서의 퀴녹살린 및 피리도피라진 유도체
AU2017286379B2 (en) 2016-06-16 2021-07-01 Janssen Pharmaceutica Nv Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors
MX2019011610A (es) 2017-03-29 2019-11-08 Janssen Pharmaceutica Nv Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.
KR20210125025A (ko) 2019-02-07 2021-10-15 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希（南京）药物研发有限公司 一种戈舍瑞林杂质的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
EP2046333A4 (fr) 2006-07-24 2010-09-15 Glaxosmithkline Llc Dérivés de thiozolidinedione utilisés en tant qu'inhibiteurs de la p13-kinase
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
US20100305113A1 (en) * 2007-05-09 2010-12-02 Hans-Georg Capraro Substituted Imidazopyridazines as Lipid Kinase Inhibitors
WO2009060197A1 (fr) 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases
KR20100128305A (ko) * 2008-02-28 2010-12-07 노파르티스 아게 Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
WO2010007099A1 (fr) * 2008-07-15 2010-01-21 Cellzome Limited Dérivés de 2-aminoimidazo[1,2-b]pyridazine en tant qu’inhibiteurs de pi3k
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011058109A1 (fr) 2009-11-12 2011-05-19 Ucb Pharma S.A. Dérivés de pyrrole et d'imidazole bicycliques condensés en tant qu'inhibiteurs de kinase
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
SG188974A1 (en) * 2010-10-06 2013-06-28 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9096605B2 (en) * 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
WO2013095761A1 (fr) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Dérivés d'imidizopyridine comme inhibiteurs de la pi3 kinase
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Also Published As

Publication number Publication date
CY1122381T1 (el) 2021-01-27
US20180002336A1 (en) 2018-01-04
SI3233862T1 (sl) 2019-09-30
MA41174B1 (fr) 2019-09-30
IL252866B (en) 2020-09-30
US10087187B2 (en) 2018-10-02
RS59301B1 (sr) 2019-10-31
ES2761051T3 (es) 2020-05-18
EP3233862B1 (fr) 2019-07-03
PL3233862T3 (pl) 2020-01-31
CA2967551A1 (fr) 2016-06-23
CN107108634A (zh) 2017-08-29
JP6568588B2 (ja) 2019-08-28
LT3233862T (lt) 2019-09-10
HUE045220T2 (hu) 2019-12-30
EA029789B1 (ru) 2018-05-31
JP2017538734A (ja) 2017-12-28
EA201791396A1 (ru) 2017-10-31
AU2015366190A1 (en) 2017-05-25
AU2015366190B2 (en) 2020-01-23
WO2016097347A1 (fr) 2016-06-23
ME03517B (fr) 2020-04-20
MX2017008074A (es) 2018-01-09
MD3233862T2 (ro) 2019-11-30
DK3233862T3 (da) 2019-10-07
IL252866A0 (en) 2017-08-31
HRP20191550T1 (hr) 2019-11-29
EP3233862A1 (fr) 2017-10-25
BR112017012930A2 (pt) 2018-01-09
PT3233862T (pt) 2019-10-09
CN107108634B (zh) 2020-09-15
KR20170095239A (ko) 2017-08-22

Similar Documents

Publication Publication Date Title
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
IL282167A (en) Metabolized carbonucleosides and their use for cancer treatment
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
MA48448A (fr) Dérivés de quinazoline utilisés pour traiter le vih
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
DK3094631T3 (da) Pyrimidinyloxybenzenderivater som herbicider
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA54254A (fr) Dérivés de benzodiazépine cytotoxique